Stock MRTX MIRATI THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Mirati Therapeutics

Equities

MRTX

US60468T1051

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Mirati Therapeutics

British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says RE
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Biotechnology Select Industry Index CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P TMI Index CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Global BMI Index CI
Bristol-Myers Squibb Closes Acquisition of Mirati Therapeutics MT
Bristol-Myers Squibb Closes Mirati Therapeutics Acquisition MT
Bristol Myers: acquisition of Mirati Therapeutics finalized CF
Mirati Therapeutics, Inc. Announces Management Changes CI
Mirati Therapeutics, Inc.(NasdaqGM:MRTX) dropped from NASDAQ Composite Index CI
Bristol-Myers Squibb Company completed the acquisition of Mirati Therapeutics, Inc. from a group of shareholders. CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index CI
Mirati Therapeutics' Krazati Lung Cancer Treatment Gets EU Conditional Marketing Authorization MT
Bristol Myers expects to launch 16 new products through 2030 - CEO RE
Immunome Appoints Phil Roberts as Chief Technical Officer MT
US FDA turns down Amgen lung cancer drug Lumakras for full approval RE
Bristol-Myers Agrees Deal to Buy RayzeBio for About $4.1 Billion MT
Bristol-Myers Squibb Strikes $14 Billion Deal to Acquire Karuna Therapeutics MT
North American Morning Briefing : Stock Futures -2- DJ
Citigroup Downgrades Mirati Therapeutics to Neutral From Buy, Raises Price Target to $59 From $48 MT
Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure CI
North American Morning Briefing : Stock Futures -2- DJ
Stifel Downgrades Mirati Therapeutics to Hold From Buy, Cuts Price Target to $59 From $83 MT
Earnings Flash (MRTX) MIRATI THERAPEUTICS Posts Q3 Revenue $16.4M MT
Mirati Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Rising Late Afternoon MT

Chart Mirati Therapeutics

Chart Mirati Therapeutics
More charts

Company Profile

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. MRTX Stock
  4. News Mirati Therapeutics
  5. Mirati Therapeutics : Stifel Starts Mirati Therapeutics at Buy With $202 Price Target